<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662017000600754</article-id>
<article-id pub-id-type="doi">10.24245/mim.v33i6.1222</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estratificación de riesgo de muerte a 28 días en pacientes con infarto agudo de miocardio con base en sus concentraciones séricas de copeptina]]></article-title>
<article-title xml:lang="en"><![CDATA[Early death risk stratification in post-myocardial infarction patients based on plasma copeptin levels.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Godínez-Baca]]></surname>
<given-names><![CDATA[LE.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luna-Pérez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Metropolitano  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles Metropolitano  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>6</numero>
<fpage>754</fpage>
<lpage>763</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662017000600754&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662017000600754&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662017000600754&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  ANTECEDENTES: la copeptina es un biomarcador reciente que ha demostrado su utilidad en el diagnóstico temprano de pacientes con infarto agudo de miocardio; sin embargo, no se ha establecido su utilidad en el pronóstico de la supervivencia a corto plazo en estos pacientes.  OBJETIVO: determinar el valor pronóstico de la copeptina en la predicción de muerte temprana (28 días) en pacientes posinfarto agudo de miocardio.  MATERIAL Y MÉTODO: estudio prospectivo, observacional, realizado del 1 de enero de 2014 al 30 de septiembre de 2015 en una cohorte de pacientes con infarto agudo de miocardio, en el que se cuantificó la copeptina sérica inicial y se analizó la mortalidad en 28 días, ajustada con factores de riesgo conocidos.  RESULTADOS: se incluyeron 34 pacientes que se clasificaron en riesgo bajo si tenían concentraciones séricas de copeptina iniciales &#8804; 12 pmol/L; en riesgo intermedio entre 12.1 y 32.5 pmol/L y en riesgo alto &#8805; 32.5 pmol/L, con mortalidad de 0, 15 y 30%, respectivamente. Se encontró una razón de riesgos entre altos y bajos ajustado a factores de confusión de 15.9 (intervalo de confianza a 95% [IC95%] de 1.3 a 190; p = 0.02 por análisis multivariable de regresión de Cox).  CONCLUSIONES: la elevación de copeptina está directamente relacionada con el riesgo de muerte temprana en pacientes posinfarto agudo de miocardio y puede usarse como marcador de pronóstico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  BACKGROUND: Copeptin is a novel biomarker that has demonstrated good diagnostic performance in the early diagnosis of patients with acute coronary syndrome; however, its prognostic performance in the short-term survival (28 days) has not been established.  OBJECTIVE: To determine the prognostic performance of copeptin for 28 day-mortality in patients with acute coronary syndrome.  MATERIAL AND METHOD: A prospective, observational cohort of patients with acute coronary syndrome was done from January 1st 2014 to November 30 2015, measuring copeptin at presentation, registering deaths and event-free survivors over 28 days.  RESULTS: Thirty-four patients were included, stratified as having low risk of death if copeptin was &#8804; 12 pmol/L, intermediate risk between 12.1 and 32.5 pmol/L, and high risk &#8805; 32.5 pmol/L, with a mortality of 0%, 15% and 30%, respectively; hazard ratio between high and low adjusted to confuse factors of 15.9 (CI95% 1.3-190; p = 0.02, Cox multivariable regression model).  CONCLUSION: Elevated concentrations of copeptin are directly proportional to a higher risk of all-cause mortality, hence it could be used as a prognostic marker.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[copeptina]]></kwd>
<kwd lng="es"><![CDATA[infarto agudo de miocardio]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="es"><![CDATA[pronóstico]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[copeptin]]></kwd>
<kwd lng="en"><![CDATA[acute coronary syndrome]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="en"><![CDATA[prognostic marker]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez Ríos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Infarto agudo de miocardio: documento de Postura. Academia Nacional de Medicina]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Ciudad de México ]]></publisher-loc>
<publisher-name><![CDATA[Intersistemas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huerta Robles]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología de los síndromes coronarios agudos]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2007</year>
<volume>77</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>214-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Von Haehling]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Papassotiriou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Morgenthaler]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease]]></article-title>
<collab>y col</collab>
<source><![CDATA[Int J Cardiol]]></source>
<year>2012</year>
<volume>162</volume>
<page-range>27-32</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maisel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Neath]]></surname>
<given-names><![CDATA[SX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Copeptin helps in the early detection of patients with acute myocardial infarction primary results of the CHOPIN trial]]></article-title>
<collab>y col</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>62</volume>
<page-range>150-60</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wildi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zellweger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Twerenbold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incremental value of copeptin to highly sensitive cardiac troponin I for rapid rule out of myocardial infarction]]></article-title>
<collab>y col</collab>
<source><![CDATA[Int J Cardiol]]></source>
<year>2015</year>
<volume>190</volume>
<page-range>170-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Maisel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased 90 day mortality in patients with elevated copeptin secondary results from the biomarkers in acute heart failure (BACH) study]]></article-title>
<collab>y col</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>10A</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Squire]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[SQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling and clinical heart failure in survivors of myocardial infarction]]></article-title>
<source><![CDATA[J Cardiac Fail]]></source>
<year>2008</year>
<volume>14</volume>
<page-range>739-45</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Von Haehling]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C- terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction results from the OPTIMAAL study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2009</year>
<volume>30</volume>
<page-range>1187-94</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yalta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yalta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sivri]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Copeptin and cardiovascular disease a review of a novel neurohormone]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2013</year>
<month>09</month>
<day>01</day>
<volume>167</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1750-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reinstadler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Klug]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Feistritzer]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Copeptin testing in acute myocardial infarction ready for routine use?]]></article-title>
<source><![CDATA[Dis Markers]]></source>
<year>2014</year>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Christ-Crain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Copeptin a new and promising diagnostic and prognostic marker]]></article-title>
<source><![CDATA[Critical Care]]></source>
<year>2008</year>
<volume>12</volume>
<page-range>117</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marston]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maisel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognostic value of copeptin in patients with acute chest pain]]></article-title>
<source><![CDATA[Expert Rev Cardiovasc]]></source>
<year>2014</year>
<volume>12</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1237-42</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thelin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Borna]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Erlinge]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The combination of high sensitivity troponin T and copeptin facilitates early rule out of ACS a prospective observational study]]></article-title>
<source><![CDATA[BMC Cardiovasc Disord]]></source>
<year>2013</year>
<volume>13</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slagman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Searle]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2015</year>
<volume>61</volume>
<page-range>1273-82</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vafaie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Biener]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addition of copeptin improves diagnostic performance of point of care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction- A pilot study]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2015</year>
<page-range>26-30</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[O'Brien]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction peptide (LAMP) study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>115</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>2103-10</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balmelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meune]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Twerenbold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men]]></article-title>
<collab>y col</collab>
<source><![CDATA[Am Heart J]]></source>
<year>2013</year>
<volume>166</volume>
<page-range>30-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zellweger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wildi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Twerenbold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of copeptin and high sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2015</year>
<volume>190</volume>
<page-range>190-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hillinger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Twerenbold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jaeger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing early rule-out strategies for acute myocardial infarction utility of 1 hour copeptin]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2015</year>
<volume>61</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marston]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serial sampling of copeptin levels improves diagnois and risk stratification in patients presenting with chest pain results from the CHOPIN trial]]></article-title>
<source><![CDATA[Emerg Med J]]></source>
<year>2016</year>
<month>01</month>
<day>00</day>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Christ-Crain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The stress hormone copeptin a new prognostic biomarker in acute illness]]></article-title>
<source><![CDATA[Swiss Med Wkly]]></source>
<year>2010</year>
<volume>140</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alehagen]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Dehlstrom]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Rehfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of copeptin and N-terminal pro-BNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2011</year>
<volume>305</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2088-95</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
